Exelixis
EXEL
#1697
Rank
HK$77.41 B
Marketcap
HK$271.08
Share price
0.52%
Change (1 day)
63.87%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): HK$2.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$2.20. In 2022 the company made an earnings per share (EPS) of HK$4.44 a decrease over its 2021 EPS that were of HK$5.76.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)HK$2.22-49.86%
2022HK$4.44-22.97%
2021HK$5.76100%
2020HK$2.88-65.09%
2019HK$8.25-53.91%
2018HK$17.90333.96%
2017HK$4.12-260.61%
2016-HK$2.57-58.75%
2015-HK$6.23-42.45%
2014-HK$10.825.3%
2013-HK$10.2743.48%
2012-HK$7.16-264.29%
2011HK$4.36-165.88%
2010-HK$6.62-32.54%
2009-HK$9.81-17.65%
2008-HK$11.9175.86%
2007-HK$6.77-25.64%
2006-HK$9.118.33%
2005-HK$8.41-42.86%
2004-HK$14.7130.34%
2003-HK$11.29-5.23%
2002-HK$11.91-0.65%
2001-HK$11.99-51.88%
2000-HK$24.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
HK$27.25 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$24.75 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
HK$14.18 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$30.90 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$110.13 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$109.63 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$14.48 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$77.83-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$6.54-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA